| Autor: |
B, Ricciuti, J V, Alessi, A, Elkrief, X, Wang, A, Cortellini, Y Y, Li, V R, Vaz, H, Gupta, F, Pecci, A, Barrichello, G, Lamberti, T, Nguyen, J, Lindsay, B, Sharma, K, Felt, S J, Rodig, M, Nishino, L M, Sholl, D A, Barbie, M V, Negrao, J, Zhang, A D, Cherniack, J V, Heymach, M, Meyerson, C, Ambrogio, P A, Jänne, K C, Arbour, D J, Pinato, F, Skoulidis, A J, Schoenfeld, M M, Awad, J, Luo |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Annals of oncology : official journal of the European Society for Medical Oncology. 33(10) |
| ISSN: |
1569-8041 |
| Popis: |
Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASClinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype.Of 2327 patients with KRAS-mutated (KRASKRAS |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
